Provided by Tiger Trade Technology Pte. Ltd.

Tyra Biosciences, Inc.

31.00
+1.545.23%
Post-market: 31.000.00000.00%18:01 EST
Volume:534.53K
Turnover:16.51M
Market Cap:1.65B
PE:-16.49
High:31.39
Open:30.30
Low:29.51
Close:29.46
52wk High:32.44
52wk Low:6.42
Shares:53.37M
Float Shares:17.22M
Volume Ratio:0.78
T/O Rate:3.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8798
EPS(LYR):-1.5114
ROE:-34.75%
ROA:-23.08%
PB:5.90
PE(LYR):-20.51

Loading ...

Company Profile

Company Name:
Tyra Biosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
60
Office Location:
2656 State Street,Carlsbad,California,United States
Zip Code:
92008
Fax:
- -
Introduction:
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Directors

Name
Position
Robert More
Chairman of the Board
Todd Harris
President,Chief Executive Officer and Director
Adele M. Gulfo
Director
Gilla Kaplan
Director
Jake Simson
Director
Melissa McCracken
Director
Rehan Verjee
Director
S. Michael Rothenberg
Director
Susan Moran
Director

Shareholders

Name
Position
Todd Harris
President,Chief Executive Officer and Director
Bhavesh Ashar
Chief Operating Officer
Alan Fuhrman
Chief Financial Officer
Daniel Bensen
Chief Discovery Officer
Douglas Warner
Chief Medical Officer